Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis.
Monika HebeisenAlmut SchererRaphael MicheroliMichael J NissenGiorgio TamborriniBurkhard MöllerPascal ZuffereyPascale ExerAdrian CiureaPublished in: PloS one (2019)
In axial spondyloarthritis, drug survival with standard doses of different TNF inhibitors is comparable.